Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Anervan Novum

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Klorcyklizin Testmiljö

Klorcyklizin

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Asker C, Norstedt Wikner B, Källén B. Use of antiemetic drugs during pregnancy in Sweden. Eur J Clin Pharmacol 2005;61:899-906.

  2. Mazzotta P, Magee LA. A risk-benefit assessment of pharmacological and nonpharmacological treatments for nausea and vomiting of pregnancy. Drugs 2000;59:781-800.

  3. Källen B. Use of antihistamine drugs in early pregnancy and delivery outcome. J Maternal-Fetal Neonatal Med 2002;11:146-52.

  1. Asker C, Norstedt Wikner B, Källén B. Use of antiemetic drugs during pregnancy in Sweden. Eur J Clin Pharmacol 2005;61:899-906.
  2. Mazzotta P, Magee LA. A risk-benefit assessment of pharmacological and nonpharmacological treatments for nausea and vomiting of pregnancy. Drugs 2000;59:781-800.
  3. Källen B. Use of antihistamine drugs in early pregnancy and delivery outcome. J Maternal-Fetal Neonatal Med 2002;11:146-52.
2 2
2 2

Ergotamin Testmiljö

Ergotamin

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Briggs G, Freeman RK, Towers CV, Forinash AB. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. 11th ed; 2017.

  2. Bánhidy F, Acs N, Puhó E, Czeizel AE. Ergotamine treatment during pregnancy and a higher rate of low birthweight and preterm birth. Br J Clin Pharmacol 2007;64:510-6.

  3. Kallen B, Lygner PE. Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan. Headache 2001;41:351-6.

  4. Källén B, Nilsson E, Otterblad Olausson P. Delivery outcome after maternal use of drugs for migraine: a register study in Sweden. Drug Saf. 2011;34(8):691-703.

  5. Acs N, Bánhidy F, Puhó E, Czeizel AE A possible dose-dependent teratogenic effect of ergotamine. Reprod Toxicol. 2006;22:551-2.

  6. Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Publishing Sciences Group, Littleton, Mass. 1977.

  7. Bérard A, Kori S . Dihydroergotamine (DHE) use during gestation and the risk of adverse pregnancy outcomes. Headache. 2012 05 21;7(52):1085-93.

  1. Briggs G, Freeman RK, Towers CV, Forinash AB. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. 11th ed; 2017.
  2. Bánhidy F, Acs N, Puhó E, Czeizel AE. Ergotamine treatment during pregnancy and a higher rate of low birthweight and preterm birth. Br J Clin Pharmacol 2007;64:510-6.
  3. Kallen B, Lygner PE. Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan. Headache 2001;41:351-6.
  4. Källén B, Nilsson E, Otterblad Olausson P. Delivery outcome after maternal use of drugs for migraine: a register study in Sweden. Drug Saf. 2011;34(8):691-703.
  5. Acs N, Bánhidy F, Puhó E, Czeizel AE A possible dose-dependent teratogenic effect of ergotamine. Reprod Toxicol. 2006;22:551-2.
  6. Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Publishing Sciences Group, Littleton, Mass. 1977.
  7. Bérard A, Kori S . Dihydroergotamine (DHE) use during gestation and the risk of adverse pregnancy outcomes. Headache. 2012 05 21;7(52):1085-93.
2 2
2 2

Koffein Testmiljö

Koffein

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Chen LW, Wu Y, Neelakantan N, Chong MF, Pan A, van Dam RM. Maternal caffeine intake during pregnancy and risk of pregnancy loss: a categorical and dose-response meta-analysis of prospective studies. Public Health Nutr. 2016;19:1233-44.

  2. Wisborg K, Kesmodel U, Bech BH et al. Maternal consumption of coffee during pregnancy and stillbirth and infant death in first year of life: prospective study. BMJ 2003;326:420-2.

  3. Cnattingius S, Signorello LB, Annerén G, Clausson B, Ekbom A, Ljunger E et al. Caffeine intake and the risk of first-trimester spontaneous abortion. New Engl J Med 2000;343:1839-45.

  4. Christian MS, Brent RL. Teratogen update: Evaluation of the reproductive and developmental risks of caffeine. Teratology 2001;64:51-78.

  5. Grosso LM, Rosenberg KD, Belanger K, Saftlas AF, Leaderer B, Bracken MB. Maternal caffeine intake and intrauterine growth retardation. Epidemiology 2001;12:447-55.

  6. Sengpiel V, Elind E, Bacelis J, Nilsson S, Grove J, Myhre R et al. Maternal caffeine intake during pregnancy is associated with birth weight but not with gestational length: results from a large prospective observational cohort study. BMC Med. 2013;11(0):42.

  7. Wikoff D, Welsh BT, Henderson R, Brorby GP, Britt J, Myers E et al. Systematic review of the potential adverse effects of caffeine consumption in healthy adults, pregnant women, adolescents, and children. Food Chem Toxicol. 2017;109(0):585-648.

  8. Koffein – råd till gravida och ammande 2019. Livsmedelsverket [www]. [cited 2020-03-10].

  1. Chen LW, Wu Y, Neelakantan N, Chong MF, Pan A, van Dam RM. Maternal caffeine intake during pregnancy and risk of pregnancy loss: a categorical and dose-response meta-analysis of prospective studies. Public Health Nutr. 2016;19:1233-44.
  2. Wisborg K, Kesmodel U, Bech BH et al. Maternal consumption of coffee during pregnancy and stillbirth and infant death in first year of life: prospective study. BMJ 2003;326:420-2.
  3. Cnattingius S, Signorello LB, Annerén G, Clausson B, Ekbom A, Ljunger E et al. Caffeine intake and the risk of first-trimester spontaneous abortion. New Engl J Med 2000;343:1839-45.
  4. Christian MS, Brent RL. Teratogen update: Evaluation of the reproductive and developmental risks of caffeine. Teratology 2001;64:51-78.
  5. Grosso LM, Rosenberg KD, Belanger K, Saftlas AF, Leaderer B, Bracken MB. Maternal caffeine intake and intrauterine growth retardation. Epidemiology 2001;12:447-55.
  6. Sengpiel V, Elind E, Bacelis J, Nilsson S, Grove J, Myhre R et al. Maternal caffeine intake during pregnancy is associated with birth weight but not with gestational length: results from a large prospective observational cohort study. BMC Med. 2013;11(0):42.
  7. Wikoff D, Welsh BT, Henderson R, Brorby GP, Britt J, Myers E et al. Systematic review of the potential adverse effects of caffeine consumption in healthy adults, pregnant women, adolescents, and children. Food Chem Toxicol. 2017;109(0):585-648.
  8. Koffein – råd till gravida och ammande 2019. Livsmedelsverket [www]. [cited 2020-03-10].